Immunotech Biopharm Ltd 6978.HK Stock
Immunotech Biopharm Ltd Price Chart
Immunotech Biopharm Ltd 6978.HK Financial and Trading Overview
| Immunotech Biopharm Ltd stock price | 3.5 HKD |
| Previous Close | 4.68 HKD |
| Open | 4.75 HKD |
| Bid | 4.73 HKD x N/A |
| Ask | 4.75 HKD x N/A |
| Day's Range | 4.59 - 4.99 HKD |
| 52 Week Range | 3.21 - 9.2 HKD |
| Volume | 132K HKD |
| Avg. Volume | 415.08K HKD |
| Market Cap | 2.44B HKD |
| Beta (5Y Monthly) | 0.878397 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7 HKD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
6978.HK Valuation Measures
| Enterprise Value | 2.38B HKD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 4.8076925 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -10.315 |
Trading Information
Immunotech Biopharm Ltd Stock Price History
| Beta (5Y Monthly) | 0.878397 |
| 52-Week Change | -7.32% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 9.2 HKD |
| 52 Week Low | 3.21 HKD |
| 50-Day Moving Average | 4.04 HKD |
| 200-Day Moving Average | 4.86 HKD |
6978.HK Share Statistics
| Avg. Volume (3 month) | 415.08K HKD |
| Avg. Daily Volume (10-Days) | 334.6K HKD |
| Shares Outstanding | 514.58M |
| Float | N/A |
| Short Ratio | N/A |
| % Held by Insiders | 62.47% |
| % Held by Institutions | 0.28% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -17.33% |
| Return on Equity (ttm) | -48.30% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -231112992 HKD |
| Net Income Avi to Common (ttm) | -318108992 HKD |
| Diluted EPS (ttm) | -0.68 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 79.46M HKD |
| Total Cash Per Share (mrq) | 0.15 HKD |
| Total Debt (mrq) | 149.81M HKD |
| Total Debt/Equity (mrq) | 29.58 HKD |
| Current Ratio (mrq) | 0.567 |
| Book Value Per Share (mrq) | 0.988 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -180922000 HKD |
| Levered Free Cash Flow (ttm) | -146340256 HKD |
Profile of Immunotech Biopharm Ltd
| Country | Hong Kong |
| State | N/A |
| City | Beijing |
| Address | Guosheng Technology Park |
| ZIP | N/A |
| Phone | N/A |
| Website | https://www.eaal.net |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 246 |
Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. Its core product is EAL, a multi-target cellular immunotherapy product that is in Phase II clinical trials for the prevention of postsurgical recurrence of liver cancer. The company is also conducting pre-clinical and clinical trial studies for EAL to treat lung cancer, glioma, gastric cancer, and colorectal cancer. In addition, it develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia; RC19D2 for non-hodgkin lymphoma; and TCR-T cell series products to treat solid tumors. Further, the company's pre-clinical products include aT19 to treat acute lymphoblastic leukaemia; CAR-T-43 for T cell leukaemia and T cell lymphoma; CAR-T-22 for B lymphocyte leukaemia; CAR-T-BCMA to treat multiple myeloma; CAR-T-ENX for solid tumors; TCR800 to treat renal cancer; and EBV, CMV specific T cells for EBV/CMV infection. Immunotech Biopharm Ltd was founded in 2006 and is headquartered in Beijing, the People's Republic of China.
Q&A For Immunotech Biopharm Ltd Stock
What is a current 6978.HK stock price?
Immunotech Biopharm Ltd 6978.HK stock price today per share is 3.5 HKD.
How to purchase Immunotech Biopharm Ltd stock?
You can buy 6978.HK shares on the HKSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Immunotech Biopharm Ltd?
The stock symbol or ticker of Immunotech Biopharm Ltd is 6978.HK.
Which industry does the Immunotech Biopharm Ltd company belong to?
The Immunotech Biopharm Ltd industry is Biotechnology.
How many shares does Immunotech Biopharm Ltd have in circulation?
The max supply of Immunotech Biopharm Ltd shares is 514.58M.
What is Immunotech Biopharm Ltd Price to Earnings Ratio (PE Ratio)?
Immunotech Biopharm Ltd PE Ratio is now.
What was Immunotech Biopharm Ltd earnings per share over the trailing 12 months (TTM)?
Immunotech Biopharm Ltd EPS is -0.7 HKD over the trailing 12 months.
Which sector does the Immunotech Biopharm Ltd company belong to?
The Immunotech Biopharm Ltd sector is Healthcare.